EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Thymidylate synthase disruption to limit cell proliferation in cell therapies

Rocio Sartori-Maldonado, Hossam Montaser, Inkeri Soppa, Solja Eurola, Juhana Juutila, Melanie Balaz, Henri Puttonen, Timo Otonkoski, Jonna Saarimäki-Vire, Kirmo Wartiovaara

Molecular Therapy · 2024

DOI: 10.1016/j.ymthe.2024.06.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Rocio Sartori-Maldonado und 9 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland. Hauptthemen laut MEDLINE: Cell Proliferation, Thymidine, Cell Differentiation, Thymidylate Synthase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HUS Group, Finnish Cultural Foundation, Helsingin Yliopisto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stem and progenitor cells hold great promise for regenerative medicine and gene therapy approaches. However, transplantation of living cells entails a fundamental risk of unwanted growth, potentially exacerbated by CRISPR-Cas9 or other genetic manipulations. Here, we describe a safety system to control cell proliferation while allowing robust and efficient cell manufacture, without any added genetic elements. Inactivating TYMS, a key nucleotide metabolism enzyme, in several cell lines resulted in cells that proliferate only when supplemented with exogenous thymidine. Under supplementation, TYMS-/--pluripotent stem cells proliferate, produce teratomas, and successfully differentiate into potentially therapeutic cell types such as pancreatic β cells. Our results suggest that supplementation with exogenous thymidine affects stem cell proliferation, but not the function of stem cell-derived cells. After differentiation, postmitotic cells do not require thymidine in vitro or in vivo, as shown by the production of functional human insulin in mice up to 5 months after implantation of stem cell-derived pancreatic tissue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell ProliferationThymidineCell DifferentiationThymidylate SynthaseHumansAnimalsMiceInsulin-Secreting CellsCell- and Tissue-Based TherapyCell LinePluripotent Stem CellsCRISPR-Cas Systems

Stichwörter der Autor:innen

DNA synthesisTYMSbeta-cell differentiationcell therapydiabeteshuman pluripotent stem cellsproliferationsafety switch

Substanzen

ThymidineThymidylate Synthase

Autor:innen und Institutionen

  • Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.
  • Faculty of Biological and Environmental Sciences University of Helsinki, 00790 Helsinki, Finland; Institute of Biotechnology, Helsinki Institute of Life Science, University of Helsinki, 00790 Helsinki, Finland.
  • Department of Pathology, Helsinki University Hospital, 00290 Helsinki, Finland.
  • Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland; Children's Hospital, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland.
  • Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland; Clinical Genetics, Helsinki University Hospital, 00290 Helsinki, Finland. Electronic address: kirmo.warti…

Förderung

  • HUS Group
  • Finnish Cultural Foundation
  • Helsingin Yliopisto
  • K Albin Johansson Foundation
  • Diabetes Research Foundation
  • Signe and Ane Gyllenberg Foundation
  • Ida Mont Fundation
  • Bo and Kerstin Hjelt Diabetes Foundation

Zitieren

APA

Sartori-Maldonado, R., Montaser, H., Soppa, I., Eurola, S., Juutila, J., Balaz, M., Puttonen, H., Otonkoski, T., Saarimäki-Vire, J., & Wartiovaara, K. (2024). Thymidylate synthase disruption to limit cell proliferation in cell therapies. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.06.014

Vancouver

Sartori-Maldonado R, Montaser H, Soppa I, Eurola S, Juutila J, Balaz M, et al. Thymidylate synthase disruption to limit cell proliferation in cell therapies. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.06.014

BibTeX
@article{SartoriMaldonado2024,
  author = {Sartori-Maldonado, Rocio and Montaser, Hossam and Soppa, Inkeri and Eurola, Solja and Juutila, Juhana and Balaz, Melanie and Puttonen, Henri and Otonkoski, Timo and Saarimäki-Vire, Jonna and Wartiovaara, Kirmo},
  title = {Thymidylate synthase disruption to limit cell proliferation in cell therapies},
  journal = {Molecular Therapy},
  year = {2024},
  doi = {10.1016/j.ymthe.2024.06.014}
}
Kostenlos starten →